OpenAlex | Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment

Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment

Work

Year: 2020

Type: article

Source: Cancer Chemotherapy and Pharmacology

Authors K. OGASAWARA, William B. Smith, Christine Xu, Jian Yin, Maria Palmisano +1 more

Institutions Bristol-Myers Squibb (United States), Alliance for Multispecialty Research (United States), University of Tennessee at Knoxville, Sanofi (United States)

Cites: 22

Cited by: 7

Related to: 10

FWCI: 0.773

Citation percentile (by year/subfield): 75.21

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

Sustainable Development Goal Good health and well-being

Open Access status: closed